Literature DB >> 3899597

The renin-angiotensin system in the control of systemic arterial pressure.

A B Ribeiro, O Kohlmann, M A Saragoça, O Marson, O L Ramos.   

Abstract

The renin-angiotensin system through its active octapeptide, angiotensin II, has an important role in systemic arterial pressure control. Angiotensin II is a potent direct vasoconstrictor and is also the main regulator of aldosterone secretion. The complete analysis of the role of angiotensin II has to take into account the prevailing sodium balance for a given level of angiotensin II and also its indirect action upon the sympathetic nervous system as well as other hormonal systems. A number of studies have provided evidence for an important role for the renin-angiotensin system in renovascular hypertension, malignant and severe hypertension, as well as in mild to moderate forms of essential hypertension.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3899597     DOI： 10.2165/00003495-198500301-00003

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  34 in total

1.  Reciprocation of renin dependency with sodium volume dependency in renal hypertension.

Authors:  H Gavras; H R Brunner; H Thurston; J H Laragh
Journal:  Science       Date:  1975-06-27       Impact factor: 47.728

2.  Regional study of cerebral ventricle sensitive sites to angiotensin II.

Authors:  W E Hoffman; M I Phillips
Journal:  Brain Res       Date:  1976-07-09       Impact factor: 3.252

Review 3.  Effects of angiotensin on the central nervous system.

Authors:  W B Severs; A E Daniels-Severs
Journal:  Pharmacol Rev       Date:  1973-09       Impact factor: 25.468

4.  Two sites of cardiovascular action of angiotensin II in the brain of the dog.

Authors:  P L Gildenberg; C M Ferrario; J W McCubbin
Journal:  Clin Sci       Date:  1973-04       Impact factor: 6.124

5.  Inhibition of central angiotensin I conversion by oral captopril.

Authors:  O Marson; A B Ribeiro; S Tufik; O Kohlmann; O L Ramos
Journal:  Braz J Med Biol Res       Date:  1981-04       Impact factor: 2.590

6.  Central and peripheral indices of sympathetic activity after blood pressure lowering with enalapril (MK-421) or hydralazine in normotensive rats.

Authors:  O Kohlmann; M Bresnahan; H Gavras
Journal:  Hypertension       Date:  1984 Mar-Apr       Impact factor: 10.190

7.  Saralasin infusion in screening patients for renovascular hypertension.

Authors:  L R Krakoff; A B Ribeiro; J U Gorkin; K R Felton
Journal:  Am J Cardiol       Date:  1980-03       Impact factor: 2.778

8.  Angiotensin-converting enzyme inhibitor resets baroreceptor reflexes in conscious dogs.

Authors:  R Hatton; D Clough; K Faulkner; J Conway
Journal:  Hypertension       Date:  1981 Nov-Dec       Impact factor: 10.190

9.  Etiopathogenesis of excess methylprednisolone arterial hypertension in the rat.

Authors:  A B Ribeiro; R J Franco; O Kohlmann; O Marson; O L Ramos
Journal:  Clin Exp Hypertens       Date:  1981       Impact factor: 1.749

10.  Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension.

Authors:  T J Moore; F R Crantz; N K Hollenberg; R J Koletsky; M S Leboff; S L Swartz; L Levine; S Podolsky; R G Dluhy; G H Williams
Journal:  Hypertension       Date:  1981 Mar-Apr       Impact factor: 10.190
View more
  10 in total

1.  The effect of captopril on peripheral hemodynamics in patients with essential hypertension: comparison between oral and sublingual administration.

Authors:  C Longhini; L Ansani; G Musacci; D Mele; M Vaccari; E Baracca; P Sgobino
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

2.  Consequences of fluid loss in patients treated with ACE inhibitors.

Authors:  J McMurray; D M Matthews
Journal:  Postgrad Med J       Date:  1987-05       Impact factor: 2.401

Review 3.  End-organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function.

Authors:  Giuliano Tocci; Massimo Volpe
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

Review 4.  Quinapril. A review of its pharmacological properties, and therapeutic efficacy in cardiovascular disorders.

Authors:  A N Wadworth; R N Brogden
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 5.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

Review 6.  Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

7.  Furosemide dynamics in conscious rabbits: modulation by angiotensin II.

Authors:  W Homsy; S Marleau; P du Souich
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

Review 8.  Comparative cardiovascular effects of drugs used for hypertension.

Authors:  M Burnier; B Waeber; J Nussberger; H R Brunner
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 9.  Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.

Authors:  G L Plosker; E M Sorkin
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

10.  High salt intake damages the heart through activation of cardiac (pro) renin receptors even at an early stage of hypertension.

Authors:  Yuka Hayakawa; Takuma Aoyama; Chiharu Yokoyama; Chihiro Okamoto; Hisaaki Komaki; Shingo Minatoguchi; Masamitsu Iwasa; Yoshihisa Yamada; Itta Kawamura; Masanori Kawasaki; Kazuhiko Nishigaki; Atsushi Mikami; Fumiaki Suzuki; Shinya Minatoguchi
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.